Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Proteomika, a subsidiary of Progenika Biopharma, has signed an option agreement with Auguron Biosciences, giving them rights to exclusive access in two autoimmune disease areas to use Auguron's nucleic acid programmable protein array technology.
Subscribe to our email newsletter
The agreement allows Proteomika to manufacture and use nucleic acid programmable protein array (NAPPA) technology at Proteomika’s facilities for its internal purposes and the performance of services to partners. At any time during the period, Proteomika may exercise the option to negotiate an exclusive license to NAPPA within the field of biomarker discovery pertaining to inflammatory bowel disease and lupus.
Although the financial details were not disclosed, the companies have stated that the fundamental terms of the license are pre-agreed in the option.
Laureano Simon, CEO of Proteomika, said: “NAPPA is the perfect complementary technology to Progenika’s expertise in Molecular Diagnostics, since we will be able to discover autoantibodies in a multiplex fashion. Lupus and IBD sufferers need better biomarkers for diagnosis, prognosis and drug response.”